Canaccord Genuity Group Issues Positive Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its price target upped by Canaccord Genuity Group from $165.00 to $170.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a hold rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on the company. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $183.36.

Repligen Trading Down 2.3 %

Shares of NASDAQ:RGEN opened at $158.99 on Friday. Repligen has a 12-month low of $113.50 and a 12-month high of $203.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a fifty day simple moving average of $155.22 and a 200 day simple moving average of $148.79.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Analysts expect that Repligen will post 1.72 EPS for the current year.

Hedge Funds Weigh In On Repligen

Large investors have recently made changes to their positions in the business. GTS Securities LLC bought a new stake in shares of Repligen in the 4th quarter worth approximately $264,000. Gordian Capital Singapore Pte Ltd acquired a new position in Repligen in the fourth quarter worth approximately $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Repligen by 12.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after buying an additional 26,733 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Repligen by 6.7% during the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock worth $19,403,000 after acquiring an additional 8,500 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in shares of Repligen during the 4th quarter worth $29,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.